Post

@JAMAInternalMed

@PeterAttiaMD

@TheLancet

@RFRedberg

@BJSM_BMJ

More from @MaryanneDemasi

Maryanne Demasi, PhD

@MaryanneDemasi

Nov 27

🚨Major journal under fire for omitting Pfizer’s failed flu data in seniors

Pfizer’s mRNA flu shot failed in the over-65s, but the @NEJM never published the data — prompting calls for accountability.

STORY LINK 👇👇
@RobertKennedyJr @RetsefL
@newstart_2024 @maryhollandnyc

This week, I reported that @pfizer's mRNA flu shot offered almost no clinical benefit in adults aged 18–64 compared to a traditional flu shot. blog.maryannedemasi.com/p/pfizers-mrna…

But that was not the full story. @NEJM did not publish any data from over-65s in the same trial — the very population most at risk from influenza and the main reason these vaccines exist.

When @RetsefL discovered the missing data, he was stunned. “It seems like the reason for omitting the older participants was because the results were not favourable for the studied mRNA vaccine.”

Levi said omitting this data was “unacceptable, especially since the over-65s are among the high-risk populations that influenza vaccines aim to protect.”

Dr Eric Rubin presided over the @NEJM decision to publish a Pfizer trial that omitted vital data, allowing a reputed journal to become complicit in the same selective reporting practices that have long undermined scientific publishing.

He also sits on the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) — the same committee that may one day review Pfizer’s biological licence application for this very product.

Read 4 tweets

Maryanne Demasi, PhD

@MaryanneDemasi

Nov 25

🔴Pfizer’s mRNA flu jab flops

ANALYSIS: Pfizer’s mRNA flu shot was supposed to revive confidence in the platform. Instead, its own trial results reinforce the view that mRNA is still nowhere near ready for prime time.

FULL STORY 👇👇
@RobertKennedyJr @VPrasadMDMPH
@newstart_2024 @RobSchneider

A major new trial of @pfizer's mRNA flu shot has landed — and despite flattering headlines, it is nowhere near the breakthrough the company hoped for.

The phase 3 study, published in the @NEJM
-57 cases of influenza-like illness in the mRNA group versus 87 in the comparator group (traditional flu shot, not saline placebo), producing a relative efficacy of 35%.

The absolute difference was tiny: 0.63% of the mRNA group developed symptoms compared with 0.95% of those who received the traditional vaccine.
(0.32% abs difference)
NNV: >300 people would need to be vaccinated to prevent a single mild, self-limiting illness

nejm.org/doi/full/10.10…

The trial’s primary efficacy claim came mostly from cases adjudicated by @pfizer's own central laboratory using Pfizer’s own lab assay — the same structure used in the company’s early Covid trials.

Put simply, it's a manufacturer-funded trial, written largely by Pfizer employees & finds its best efficacy in the endpoint that requires all samples to be shipped to a Pfizer-run central lab for adjudication.
@IamBrookJackson @Jikkyleaks

Read 6 tweets

Maryanne Demasi, PhD

@MaryanneDemasi

Nov 19

🚨Prozac’s dark legacy: regulators ignored early warnings of sexual harm
Internal documents show Eli Lilly and regulators buried evidence that Prozac could permanently alter sexual development.
FULL STORY 👇👇
@maryhollandnyc @ACE_CoalitionEd @Honest_Medicine

EARLY WARNINGS
A 2005 assessment by the Dutch Medicines Evaluation Board described a disturbing pattern in Eli Lilly’s own animal studies.

It found that juvenile rats exposed to fluoxetine showed delayed sexual maturation, degeneration of testicular tissue, and hormonal disruption.

They recommended against approval, concluding the benefit–risk balance was negative.

PROMISES MADE, PROMISES BROKEN
Despite significant safety concerns, in 2006, Prozac was approved for paediatric use across Europe on the condition that @EliLillyandCo use European registries to participate in long-term studies on sexual maturation.

This was to be the TADS-Jr study. But within a few years, the study was abandoned due to lack of funding.

The UK’s @MHRAgovuk accepted that “any clinical study to investigate the effects of fluoxetine on sexual maturation would be forbiddingly hard to conduct and difficult to interpret.”

Read 7 tweets

Maryanne Demasi, PhD

@MaryanneDemasi

Nov 15

🩺The menopause moment: progress or overcorrection?
LINK 👇
As the FDA lifts its black box warning on HRT, women are now being urged to begin treatment within ten years of menopause onset. Is this shift grounded in evidence or emotion?

@DrMakaryFDA
@LadySpaulding11
@MdBreathe
@KLVeritas

When @US_FDA announced it was removing the black box warning from hormone replacement therapy (HRT), the media response was nothing short of euphoric.

Morning shows ran breathless coverage, and one female host even admitted she became “teary” after hearing the news. But is it a long-overdue correction or another swing of the pendulum from one extreme to the other?

We can’t fight bad science with worse science.
The 2002 WHI study is blamed for the collapse in HRT use. It was stopped early after investigators found a higher risk of breast cancer in women taking combined oestrogen–progestin therapy.

The study was not perfect — but you can’t counter its limitations with weaker evidence.

Read 4 tweets

Maryanne Demasi, PhD

@MaryanneDemasi

Oct 23

🧵The Weaponisation of Science
"The scientific process has been hollowed out by financial incentives, regulatory capture, and institutional cowardice."

LINK 👇👇
@MAHA_Action @Holden_Culotta @SecKennedy

CENSORSHIP
I first saw this clearly in 2013 while investigating statins. My ABC documentary questioned whether statins were being overprescribed, and it unleashed a media firestorm.

The episode was pulled after industry outrage, and I was publicly attacked. None of the critics engaged with the evidence — they simply sought to silence it.
blog.maryannedemasi.com/p/heart-of-the…

LACK OF TRANSPARENCY
The raw data underpinning statin trials are held exclusively by the Oxford-based Cholesterol Treatment Trialists (CTT) & have been released because of a legally binding agreement to block third-party access.
Hence despite millions of people taking statins daily, there has never been an independent verification of the statin trials. pubmed.ncbi.nlm.nih.gov/29353811/

Read 11 tweets

Maryanne Demasi, PhD

@MaryanneDemasi

Oct 15

🔥Inside the Henry Ford vaccine controversy
The Henry Ford Health study comparing vaccinated and unvaccinated children was never published—until Congress forced it into the open.
Here’s what it found, and why it matters.
LINK below 👇👇

@AaronSiriSG @HenryFordHealth
@MdBreathe @Jikkyleaks @DowdEdward @newstart_2024

The lead investigator, Dr Marcus Zervos, is a veteran infectious-disease specialist. During the Covid-19 pandemic, he was a regular on local news programs, promoting vaccination and defending public-health mandates.
His involvement gave the project an establishment credibility rarely seen in vaccine-safety research.

Completed in 2020, the study was unpublished until it was introduced into the congressional record on 9 September 2025 during a Senate hearing.
The Henry Ford team found vaccinated children had far higher rates of chronic disease than their unvaccinated peers.
hsgac.senate.gov/wp-content/upl…

Read 8 tweets

Share this page!

Enter URL or ID to Unroll

Maryanne Demasi, PhD

Try unrolling a thread yourself!

More from @MaryanneDemasi

Maryanne Demasi, PhD

Maryanne Demasi, PhD

Maryanne Demasi, PhD

Maryanne Demasi, PhD

Maryanne Demasi, PhD

Maryanne Demasi, PhD

Did Thread Reader help you today?

Don't want to be a Premium member but still want to support us?

Send Email!